Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""chemotherapy"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 12706
Tytuł:
A Drosophila model relevant to chemotherapy-related cognitive impairment.
Autorzy:
Torre M; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.
Bukhari H; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.
Nithianandam V; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.
Zanella CA; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA.
Mata DA; Foundation Medicine, Inc., Cambridge, MA, USA.
Feany MB; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, 75 Francis Street, Boston, MA, 02115, USA. mel_.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Nov 07; Vol. 13 (1), pp. 19290. Date of Electronic Publication: 2023 Nov 07.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents*/adverse effects
Cognitive Dysfunction*/diagnosis
Chemotherapy-Related Cognitive Impairment*
Adult ; Animals ; Humans ; Cisplatin/adverse effects ; Drosophila ; Doxorubicin/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience.
Autorzy:
Ho IW; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.; Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
Pan YL; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.; Department of Internal Medicine, En Chu Kong hospital, New Taipei city, Taiwan.
Lai JI; Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.; Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.; Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei, Taiwan.; Center of Immuno-Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.
Liu CY; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.; Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan.; Comprehensive Breast Health Center, Taipei Veterans General Hospital, Taipei, Taiwan.; Division of Transfusion Medicine, Department of Internal Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2024 Feb; Vol. 15 (4), pp. 339-346. Date of Electronic Publication: 2023 Dec 27.
Typ publikacji:
Journal Article
MeSH Terms:
Thymoma*/drug therapy
Thymoma*/pathology
Antineoplastic Agents*/therapeutic use
Thymus Neoplasms*/drug therapy
Thymus Neoplasms*/pathology
Humans ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cisplatin/therapeutic use ; Platinum/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review.
Autorzy:
Gebremariam GT; School of Pharmacy, Addis Ababa University, Zambia Street, P.O. box: 1176, Addis Ababa, Ethiopia. .
Fentie AM; School of Pharmacy, Addis Ababa University, Zambia Street, P.O. box: 1176, Addis Ababa, Ethiopia.
Beyene K; Department of Pharmaceutical and Administrative Sciences, University of Health Sciences and Pharmacy in St. Louis, St. Louis, USA.
Sander B; Institute of Health Policy, Management, and Evaluation, University of Toronto, 155 College Street, Toronto, Ontario, M5T 3M6, Canada.; Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network, 200 Elizabeth Street, Toronto, Ontario, M5G 2C4, Canada.; Institute for Clinical Evaluative Sciences, 2075 Bayview Ave, Toronto, Ontario, M4N 3M5, Canada.; Public Health Ontario, 480 University Ave, Toronto, Ontario, M5G 1V2, Canada.
Gebretekle GB; Institute of Health Policy, Management, and Evaluation, University of Toronto, 155 College Street, Toronto, Ontario, M5T 3M6, Canada.; Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network, 200 Elizabeth Street, Toronto, Ontario, M5G 2C4, Canada.; Centre for Vaccine-Preventable Diseases, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
Pokaż więcej
Źródło:
BMC health services research [BMC Health Serv Res] 2022 Dec 30; Vol. 22 (1), pp. 1600. Date of Electronic Publication: 2022 Dec 30.
Typ publikacji:
Systematic Review; Journal Article
MeSH Terms:
Chemotherapy-Induced Febrile Neutropenia*/drug therapy
Chemotherapy-Induced Febrile Neutropenia*/etiology
Chemotherapy-Induced Febrile Neutropenia*/prevention & control
Antineoplastic Agents*/adverse effects
Lymphoma*
Febrile Neutropenia*/chemically induced
Febrile Neutropenia*/prevention & control
Febrile Neutropenia*/drug therapy
Humans ; Filgrastim ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Cost-Benefit Analysis ; Polyethylene Glycols ; Recombinant Proteins ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Biomarkers of Response to Venetoclax Therapy in Acute Myeloid Leukemia.
Autorzy:
Rodríguez-Medina C; Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, 35019 Las Palmas de Gran Canaria, Spain.
Stuckey R; Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, 35019 Las Palmas de Gran Canaria, Spain.
Bilbao-Sieyro C; Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, 35019 Las Palmas de Gran Canaria, Spain.; Morphology Department, Universidad de Las Palmas de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain.
Gómez-Casares MT; Hematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, 35019 Las Palmas de Gran Canaria, Spain.; Department of Medical Sciences, Universidad de Las Palmas de Gran Canaria, 35016 Las Palmas de Gran Canaria, Spain.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 24; Vol. 25 (3). Date of Electronic Publication: 2024 Jan 24.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Leukemia, Myeloid, Acute*/pathology
Antineoplastic Agents*/therapeutic use
Sulfonamides*
Adult ; Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Biomarkers
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Vinorelbine Improves the Efficacy of Sorafenib against Hepatocellular Carcinoma: A Promising Therapeutic Approach.
Autorzy:
Ng WH; Laboratory of Molecular Endocrinology, National Cancer Centre Singapore, Singapore 168583, Singapore.
Soo KC; Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore 168583, Singapore.
Huynh H; Laboratory of Molecular Endocrinology, National Cancer Centre Singapore, Singapore 168583, Singapore.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2024 Jan 26; Vol. 25 (3). Date of Electronic Publication: 2024 Jan 26.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/metabolism
Liver Neoplasms*/metabolism
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Humans ; Animals ; Mice ; Sorafenib/pharmacology ; Sorafenib/therapeutic use ; Vinorelbine/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Apoptosis ; Cell Line, Tumor ; Cell Proliferation ; Xenograft Model Antitumor Assays
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Budget impact analysis of venetoclax for the management of acute myeloid leukemia from the perspective of the social security and the private sector in Argentina.
Autorzy:
Palacios A; Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.; Department of Economics, Universidad de Buenos Aires, Buenos Aires, Argentina.; Centre for Health Economics (CHE), University of York, York, United Kingdom.
Espinola N; Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
Gonzalez JM; Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
Rojas-Roque C; Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.; Centre for Health Economics (CHE), University of York, York, United Kingdom.
Rivas MM; Hospital Universitario Austral, Buenos Aires, Argentina.
Kanevski D; AbbVie Argentina, Buenos Aires, Argentina.
Morisset P; AbbVie Argentina, Buenos Aires, Argentina.
Augustovski F; Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
Pichon-Riviere A; Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
Bardach A; Department of Health Technology Assessment and Health Economics, Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Jan 04; Vol. 19 (1), pp. e0295798. Date of Electronic Publication: 2024 Jan 04 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Leukemia, Myeloid, Acute*/drug therapy
Antineoplastic Agents*/economics
Antineoplastic Agents*/therapeutic use
Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Argentina ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Private Sector
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy and safety profile of combining antiangiogenic agents with chemotherapy in patients with advanced malignant pleural mesothelioma: A systematic review and meta-analysis of randomized controlled trials.
Autorzy:
Tian W; Department of Oncology, Zibo Central Hospital, Shandong University, Zibo, Shandong, Peoples' Republic of China.
Guo Q; Day Care Unit, Zibo Central Hospital, Shandong University, Zibo, Shandong, Peoples' Republic of China.
Fu D; Department of Oncology, Zibo Central Hospital, Shandong University, Zibo, Shandong, Peoples' Republic of China.
Ma X; Department of Internal Medicine, Zhangqiu People's Hospital, Zhangqiu, Shandong, People' Republic of China.
Wang R; Department of Oncology, Zibo Central Hospital, Shandong University, Zibo, Shandong, Peoples' Republic of China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Dec 21; Vol. 18 (12), pp. e0295745. Date of Electronic Publication: 2023 Dec 21 (Print Publication: 2023).
Typ publikacji:
Meta-Analysis; Systematic Review; Journal Article
MeSH Terms:
Mesothelioma, Malignant*/drug therapy
Antineoplastic Agents*/therapeutic use
Humans ; Angiogenesis Inhibitors/adverse effects ; Randomized Controlled Trials as Topic ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical characteristics and treatment outcomes of HER2 mutation and HER2 fusion in 22 patients with advanced breast cancer.
Autorzy:
Mu Y; Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China.
Meng Y; Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China.
Du Y; Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China.
Liu X; Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China.
Zhang J; Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, Shanghai, China.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2023 Dec; Vol. 14 (34), pp. 3381-3388. Date of Electronic Publication: 2023 Oct 20.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/genetics
Breast Neoplasms*/metabolism
Antineoplastic Agents*/therapeutic use
Humans ; Female ; Trastuzumab/therapeutic use ; Retrospective Studies ; Treatment Outcome ; Mutation ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
PD-1 blockade combined with decitabine to treat refractory peripheral T-cell lymphoma not otherwise specified: A case report and review of literature.
Autorzy:
Han X; Medical Center of Hematology, Xinqiao Hospital of Army Medical University, State Key Laboratory of Trauma, Burns and Combined Injury, PLA Blood Disease Center, Chongqing Key Discipline of Medicine, Chongqing, China.
Liu X
Zhang C
Wen Q
Zhang X
Pokaż więcej
Źródło:
Journal of cancer research and therapeutics [J Cancer Res Ther] 2023 Dec 01; Vol. 19 (6), pp. 1680-1684. Date of Electronic Publication: 2023 Dec 28.
Typ publikacji:
Review; Case Reports; Journal Article
MeSH Terms:
Lymphoma, T-Cell, Peripheral*/diagnosis
Lymphoma, T-Cell, Peripheral*/drug therapy
Lymphoma, T-Cell, Peripheral*/pathology
Antineoplastic Agents*/therapeutic use
Female ; Humans ; Adult ; Decitabine/therapeutic use ; Programmed Cell Death 1 Receptor ; Neoplasm Recurrence, Local/drug therapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia.
Autorzy:
Xu X; Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.
Liu R; Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.
He A; Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.
Wang F; Department of Hematology, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, People's Republic of China.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2023 Dec; Vol. 28 (1), pp. 2265206. Date of Electronic Publication: 2023 Oct 05.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Leukemia, Myeloid, Acute*/pathology
Humans ; Young Adult ; Retrospective Studies ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Recent Updates in Venetoclax Combination Therapies in Pediatric Hematological Malignancies.
Autorzy:
Leśniak M; Student Scientific Society of Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland.
Lipniarska J; Student Scientific Society of Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland.
Majka P; Student Scientific Society of Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland.
Lejman M; Independent Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland.
Zawitkowska J; Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Nov 24; Vol. 24 (23). Date of Electronic Publication: 2023 Nov 24.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Leukemia, Myeloid, Acute*/pathology
Hematologic Neoplasms*/drug therapy
Hematologic Neoplasms*/etiology
Adult ; Humans ; Child ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Bridged Bicyclo Compounds, Heterocyclic/therapeutic use ; Proto-Oncogene Proteins c-bcl-2
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A phase I study of the combination of atezolizumab, tiragolumab, and stereotactic body radiation therapy in patients with metastatic multiorgan cancer.
Autorzy:
Roussot N; Department of Medical Oncology, Center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France.; Cancer Biology Transfer Platform, Dijon, France.; University of Burgundy-Franche Comté, Dijon, France.; UMR INSERM 1231, Dijon, France.
Fumet JD; Department of Medical Oncology, Center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France. .; Cancer Biology Transfer Platform, Dijon, France. .
Limagne E; Cancer Biology Transfer Platform, Dijon, France.; GIMI Genetic and Immunology Medical Institute, Dijon, France.; University of Burgundy-Franche Comté, Dijon, France.; UMR INSERM 1231, Dijon, France.
Thibaudin M; Cancer Biology Transfer Platform, Dijon, France.; GIMI Genetic and Immunology Medical Institute, Dijon, France.; UMR INSERM 1231, Dijon, France.
Hervieu A; Department of Medical Oncology, Center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France.
Hennequin A; Department of Medical Oncology, Center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France.
Zanetta S; Department of Medical Oncology, Center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France.
Dalens L; Department of Medical Oncology, Center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France.
Fourrier T; Department of Medical Oncology, Center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France.
Galland L; Department of Medical Oncology, Center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France.
Jacob P; Department of Medical Oncology, Center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France.
Bertaut A; Department of Epidemiology and Biostatistics, Center GF Leclerc, Dijon, France.
Rederstorff E; Department of Epidemiology and Biostatistics, Center GF Leclerc, Dijon, France.
Chevalier C; Department of Radiotherapy, Center GF Leclerc, Dijon, France.
Ghirardi S; Department of Radiotherapy, Center GF Leclerc, Dijon, France.
Gilbert E; Department of Radiotherapy, Center GF Leclerc, Dijon, France.
Khoukaz A; Department of Radiotherapy, Center GF Leclerc, Dijon, France.
Martin E; Department of Radiotherapy, Center GF Leclerc, Dijon, France.
Nicolet C; Department of Radiotherapy, Center GF Leclerc, Dijon, France.
Quivrin M; Department of Radiotherapy, Center GF Leclerc, Dijon, France.
Thibouw D; Department of Radiotherapy, Center GF Leclerc, Dijon, France.
Vulquin N; Department of Radiotherapy, Center GF Leclerc, Dijon, France.
Truc G; Department of Radiotherapy, Center GF Leclerc, Dijon, France.
Rouffiac M; Department of Radiotherapy, Center GF Leclerc, Dijon, France.
Ghiringhelli F; Department of Medical Oncology, Center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France.; Cancer Biology Transfer Platform, Dijon, France.; GIMI Genetic and Immunology Medical Institute, Dijon, France.; University of Burgundy-Franche Comté, Dijon, France.; UMR INSERM 1231, Dijon, France.
Mirjolet C; UMR INSERM 1231, Dijon, France.; Radiation Oncology Department, Preclinical Radiation Therapy and Radiobiology Unit, Center GF Leclerc, Unicancer, Dijon, France.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Nov 09; Vol. 23 (1), pp. 1080. Date of Electronic Publication: 2023 Nov 09.
Typ publikacji:
Clinical Trial, Phase I; Journal Article
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/radiotherapy
Carcinoma, Non-Small-Cell Lung*/drug therapy
Carcinoma, Renal Cell*/drug therapy
Radiosurgery*/adverse effects
Lung Neoplasms*/radiotherapy
Lung Neoplasms*/drug therapy
Antineoplastic Agents*/therapeutic use
Kidney Neoplasms*/drug therapy
Head and Neck Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/drug therapy
Humans ; B7-H1 Antigen ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Improved risk prediction of chemotherapy-induced neutropenia-model development and validation with real-world data.
Autorzy:
Venäläinen MS; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Heervä E; Department of Oncology, Turku University Hospital and FICAN West, Turku, Finland.; University of Turku, Turku, Finland.
Hirvonen O; Department of Oncology, Turku University Hospital and FICAN West, Turku, Finland.; Department of Clinical Oncology, University of Turku, Turku, Finland.; Palliative Center, Turku University Hospital, Turku, Finland.
Saraei S; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Suomi T; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.
Mikkola T; Tays Research Services, Clinical Informatics Team, Tampere University Hospital and University of Tampere, Tampere, Finland.
Bärlund M; Department of Oncology, Tays Cancer Centre, Tampere University Hospital, Tampere, Finland.; Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Jyrkkiö S; Department of Oncology, Turku University Hospital and FICAN West, Turku, Finland.
Laitinen T; Department of Pulmonary Medicine, University of Turku and Turku University Hospital, Turku, Finland.; Administration Center, Tampere University Hospital and University of Tampere, Tampere, Finland.
Elo LL; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.; Institute of Biomedicine, University of Turku, Turku, Finland.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2022 Feb; Vol. 11 (3), pp. 654-663. Date of Electronic Publication: 2021 Dec 03.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents*/adverse effects
Chemotherapy-Induced Febrile Neutropenia*/diagnosis
Chemotherapy-Induced Febrile Neutropenia*/epidemiology
Chemotherapy-Induced Febrile Neutropenia*/etiology
Neoplasms*/drug therapy
Antineoplastic Combined Chemotherapy Protocols ; Cohort Studies ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Anti-tumor activity of selinexor in combination with antineoplastic agents in chronic lymphocytic leukemia.
Autorzy:
Vitale C; University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126, Turin, Italy.; Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Turin, Italy.
Griggio V; University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126, Turin, Italy.; Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Turin, Italy.
Todaro M; University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126, Turin, Italy.; Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Turin, Italy.
Riganti C; Department of Oncology, University of Torino, 10126, Turin, Italy.
Jones R; University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126, Turin, Italy.; Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Turin, Italy.
Boccellato E; University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126, Turin, Italy.; Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Turin, Italy.
Perutelli F; University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126, Turin, Italy.; Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Turin, Italy.
Arruga F; Department of Medical Sciences, University of Torino, 10126, Turin, Italy.
Vaisitti T; Department of Medical Sciences, University of Torino, 10126, Turin, Italy.
Efremov DG; Molecular Hematology, International Centre for Genetic Engineering and Biotechnology, 34149, Trieste, Italy.
Deaglio S; Department of Medical Sciences, University of Torino, 10126, Turin, Italy.
Landesman Y; Karyopharm Therapeutics, Newton, MA, 024559, USA.
Bruno B; University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126, Turin, Italy.; Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Turin, Italy.
Coscia M; University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, 10126, Turin, Italy. .; Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126, Turin, Italy. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Oct 07; Vol. 13 (1), pp. 16950. Date of Electronic Publication: 2023 Oct 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Leukemia, Lymphocytic, Chronic, B-Cell*/drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell*/pathology
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/therapeutic use
Animals ; Mice ; Cell Line, Tumor ; Hydrazines/pharmacology ; Hydrazines/therapeutic use ; Drug Combinations ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy.
Autorzy:
Won YW; Division of Hematology and Oncology, Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
Kang JH; Division of Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Kwon JH; Division of Hematology and Oncology, Department of Internal Medicine, Chungnam National University Sejong Hospital, Chungnam National University College of Medicine, Sejong, Korea.
Koo DH; Division of Hematology/Oncology, Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kang JH; Division of Hematology and Oncology, Department of Internal Medicine, Gyeongsang National University College of Medicine, Jinju, Korea.
Maeng CH; Division of Oncology and Hematology, Department of Internal Medicine, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Korea.
Ahn HK; Division of Medical Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea.
Oh SY; Division of Hematology and Oncology, Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Lee DW; Division of Hematology and Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Sohn J; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
Oh SY; Division of Hematology and Oncology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan University College of Medicine, Yangsan, Korea.
Lee KH; Division of Hematology and Oncology, Department of Internal Medicine, Yeungnam University Hospital, Yeungnam University College of Medicine, Daegu, Korea.
Koh SJ; Division of Hematology and Oncology, Department of Internal Medicine, Ulsan University Hospital, Ulsan University College of Medicine, Ulsan, Korea.
Lee KS; Center for Breast Cancer, Research Institute, National Cancer Center, Goyang, Korea.
Kim CK; Division of Hematology and Oncology, Department of Internal Medicine, Soonchunhyang University Hospital Bucheon, Soonchunhyang University College of Medicine, Bucheon, Korea.
Kim JY; Division of Hematology and Oncology, Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Ji JH; Division of Hematology and Oncology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea.
Kim SB; Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Ha JY; Division of Hematology and Oncology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, Korea.
Kim HY; Division of Hematology and Oncology, Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea.
Pokaż więcej
Źródło:
Cancer research and treatment [Cancer Res Treat] 2023 Oct; Vol. 55 (4), pp. 1096-1103. Date of Electronic Publication: 2023 Apr 07.
Typ publikacji:
Observational Study; Multicenter Study; Journal Article
MeSH Terms:
Antineoplastic Agents*/adverse effects
Breast Neoplasms*/drug therapy
Humans ; Female ; Docetaxel/adverse effects ; Ethanol/adverse effects ; Prospective Studies ; Patients ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients.
Autorzy:
Jiang Y; Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52, Fucheng Road, Haidian District, Beijing, 100142, China.
Zhang J; Department of Nuclear Medicine, the Affiliated Hospital of Qingdao University, Qingdao, China.
Zhong J; Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52, Fucheng Road, Haidian District, Beijing, 100142, China.
Liao H; Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52, Fucheng Road, Haidian District, Beijing, 100142, China.
Zhang J; Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52, Fucheng Road, Haidian District, Beijing, 100142, China.
Liu Y; Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52, Fucheng Road, Haidian District, Beijing, 100142, China.
Liang Y; Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52, Fucheng Road, Haidian District, Beijing, 100142, China.
Li H; Department of Breast Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, No. 52, Fucheng Road, Haidian District, Beijing, 100142, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2023 Jul 26; Vol. 23 (1), pp. 702. Date of Electronic Publication: 2023 Jul 26.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/adverse effects
Antineoplastic Agents*/therapeutic use
Breast Neoplasms*/drug therapy
Breast Neoplasms*/etiology
Neutropenia*/chemically induced
Neutropenia*/prevention & control
Female ; Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Granulocyte Colony-Stimulating Factor ; Recombinant Proteins/adverse effects ; Recombinant Proteins/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Incidence, consequences, and predictors of serious chemotherapy-induced thrombocytopenia in nasopharyngeal carcinoma.
Autorzy:
Zhang LL; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
Chen X; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
Huang YY; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
Liang CX; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
Qiang MY; Department of Head and Neck Radiotherapy, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, People's Republic of China.
Cai ZC; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
Zhan ZJ; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
Deng Y; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
Zhou JY; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
Huang HY; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
Guo X; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
Lv X; Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2023 Jul; Vol. 12 (13), pp. 14084-14093. Date of Electronic Publication: 2023 May 22.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents*/adverse effects
Nasopharyngeal Neoplasms*/pathology
Thrombocytopenia*/chemically induced
Thrombocytopenia*/epidemiology
Humans ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Incidence ; Nasopharyngeal Carcinoma/drug therapy ; Nasopharyngeal Carcinoma/pathology ; Platinum/adverse effects ; Prognosis ; Retrospective Studies
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Mind the Curve: Dose-Response Fitting Biases the Synergy Scores across Software Used for Chemotherapy Combination Studies.
Autorzy:
Fuentealba-Manosalva O; Instituto de Farmacología y Morfofisiología, Facultad de Ciencias Veterinarias, Universidad Austral de Chile, Valdivia 5110566, Chile.
Mansilla M; Instituto de Farmacología y Morfofisiología, Facultad de Ciencias Veterinarias, Universidad Austral de Chile, Valdivia 5110566, Chile.
Buelvas N; Instituto de Farmacología y Morfofisiología, Facultad de Ciencias Veterinarias, Universidad Austral de Chile, Valdivia 5110566, Chile.
Martin-Martin A; Instituto de Farmacología y Morfofisiología, Facultad de Ciencias Veterinarias, Universidad Austral de Chile, Valdivia 5110566, Chile.
Torres CG; Departamento de Ciencias Clínicas, Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile, Santiago 8820808, Chile.; Laboratorio Centralizado de Investigación Veterinaria (LaCIV), Facultad de Ciencias Veterinarias y Pecuarias, Universidad de Chile, Santiago 8820808, Chile.
López-Muñoz RA; Instituto de Farmacología y Morfofisiología, Facultad de Ciencias Veterinarias, Universidad Austral de Chile, Valdivia 5110566, Chile.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Jun 03; Vol. 24 (11). Date of Electronic Publication: 2023 Jun 03.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/pharmacology
Animals ; Dogs ; Celecoxib/pharmacology ; Drug Therapy, Combination ; Software ; Drug Combinations ; Drug Synergism ; Antineoplastic Combined Chemotherapy Protocols/pharmacology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Clinical benefit of platinum doublet combination therapy in older adults with advanced non-small cell lung cancer: A prospective multicenter study by the National Hospital Organization in Japan.
Autorzy:
Shimokawa M; Department of Biostatistics, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan.; Clinical Research Institute, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Kanazu M; Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Japan.
Saito R; Division of Respiratory Medicine, National Hospital Organization Shibukawa Medical Center, Shibukawa, Japan.
Mori M; Department of Thoracic Oncology, National Hospital Organization Osaka Toneyama Medical Center, Toyonaka, Japan.
Tamura A; Department of Respiratory Diseases, National Hospital Organization Tokyo National Hospital, Tokyo, Japan.
Okano Y; Division of Pulmonary Medicine, National Hospital Organization Kochi Hospital, Kochi, Japan.
Fujita Y; Department of Respiratory Medicine, National Hospital Organization Asahikawa Medical Center, Asahikawa, Japan.
Endo T; Department of Respiratory Medicine, National Hospital Organization Mito Medical Center, Ibaraki, Japan.
Motegi M; Department of Respiratory Medicine, National Hospital Organization Takasaki General Medical Center, Takasaki, Japan.
Takata S; Department of Respiratory Medicine, National Hospital Organization Fukuokahigashi Medical Center, Fukuoka, Japan.
Kita T; Department of Respiratory Medicine, National Hospital Organization Kanazawa Medical Center, Kanazawa, Japan.
Sukoh N; Department of Respiratory Medicine, National Hospital Organization Hokkaido Medical Center, Sapporo, Japan.
Mizuki F; Center for Clinical Research, Yamaguchi University Hospital, Yamaguchi, Japan.
Takenoyama M; Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Atagi S; Department of Thoracic Oncology, National Hospital Organization Kinki-Chuo Chest Medical Center, Sakai, Japan.
Pokaż więcej
Źródło:
Thoracic cancer [Thorac Cancer] 2023 Jun; Vol. 14 (17), pp. 1597-1605. Date of Electronic Publication: 2023 Apr 18.
Typ publikacji:
Multicenter Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Antineoplastic Agents*/therapeutic use
Humans ; Aged ; Platinum/therapeutic use ; Japan ; Prospective Studies ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Hospitals
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 12706

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies